279 related articles for article (PubMed ID: 27406232)
1. Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.
Plöthner M; Ribbentrop D; Hartman JP; Frank M
Adv Ther; 2016 Sep; 33(9):1461-80. PubMed ID: 27406232
[TBL] [Abstract][Full Text] [Related]
2. Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review.
Faruque F; Noh H; Hussain A; Neuberger E; Onukwugha E
J Manag Care Spec Pharm; 2019 Feb; 25(2):260-271. PubMed ID: 30698084
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.
Morris SA; Alsaidi AT; Verbyla A; Cruz A; Macfarlane C; Bauer J; Patel JN
Clin Pharmacol Ther; 2022 Dec; 112(6):1318-1328. PubMed ID: 36149409
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA
J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980
[TBL] [Abstract][Full Text] [Related]
6. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Unim B; Pitini E; De Vito C; D'Andrea E; Marzuillo C; Villari P
Value Health; 2020 Jan; 23(1):114-126. PubMed ID: 31952666
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation.
Turongkaravee S; Jittikoon J; Rochanathimoke O; Boyd K; Wu O; Chaikledkaew U
BMC Health Serv Res; 2021 Oct; 21(1):1042. PubMed ID: 34600523
[TBL] [Abstract][Full Text] [Related]
10. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer.
Seo MK; Cairns J
PLoS One; 2018; 13(9):e0204496. PubMed ID: 30256829
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
Verbelen M; Weale ME; Lewis CM
Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
[TBL] [Abstract][Full Text] [Related]
12. Economics of Pharmacogenetic-Guided Treatments: Underwhelming or Overstated?
Hughes DA
Clin Pharmacol Ther; 2018 May; 103(5):749-751. PubMed ID: 29435984
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Lange A; Prenzler A; Frank M; Golpon H; Welte T; von der Schulenburg JM
BMC Pulm Med; 2014 Dec; 14():192. PubMed ID: 25471553
[TBL] [Abstract][Full Text] [Related]
16. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
17. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
Rosenblat JD; Lee Y; McIntyre RS
J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
[TBL] [Abstract][Full Text] [Related]
18. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.
Frank M; Mittendorf T
Pharmacoeconomics; 2013 Mar; 31(3):215-28. PubMed ID: 23338963
[TBL] [Abstract][Full Text] [Related]
19. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
Hafner S; Haubensak S; Paul T; Zolk O
Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
[No Abstract] [Full Text] [Related]
20. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
